INTRODUCTION
Rift Valley Fever (RVF) is a viral disease transmitted by mosquitoes. The disease appears as epizootics in domestic cattle and sheep, producing widespread abortions and deaths in young animals. It is a zoonotic disease and highly infectious in Humans, (Digoutte and Peters, 1989) . The disease occurs in climatic conditions combined with rainfall every 5-25 years in nonimmune animal's populations (OIE, 2014). RVF disease is caused by Bunyavirus of the Genus Phlebovirus and transmitted by mosquitoes (OIE, 1989).
The best tool for protecting the animal population and indirectly humane being is vector control and vaccination, (Abdel-Gaffar et al., 1979), using a safe and potent inactivated vaccine. During epizootics of RVF, the use of live attenuated Smithburn vaccine is recommended (WHO, 1983) but with limitation to be used in pregnant animals due to fear from teratogenic or aborteogenic effect and ability to be converted into a virulent state (Kathryn et al., 1991) . The progress in vaccine production is directed towards the selection of the proper adjuvant that can elaborate high and long-standing immunity.Adjuvants are considered as one of the important factors in vaccine formulations that increase the immune response either humoral and cell-mediated immunity (Dalsgrrd et al., 1990) .
Montanide Gel 01 TM is generic of Montanide as water-based adjuvant designed recently to improve the efficacy of aqueous type vaccine. It was observed that using of Montanide Gel 01TM as adjuvant gave sufficient early immune response in vaccinated cattle associated with a perfect safety profile whatever the nature of the antigen (Dupuis et al., 2008) , and it was reported that the antibodies induced were higher than Aluminium-based vaccines and so it can be used associated with a wide range of antigenic media and recommended to be used as adjuvant for sensitive animal's vaccines ( This work aims to improve and enhance the immunogenicity of the locally produced inactivated RVF vaccine to induce high and long duration of immunity in vaccinated animals using Montanide Gel 01 TM as an adjuvant.
MATERIALS AND METHODS

A.MATERIALS 1.Experimental animals Sheep
Twenty-five local breed sheep 3-4-month-old were used for evaluation of their immune response to the prepared vaccines. All of these animals were screened using SNT and ELISA and proved to be free from RVF antibodies. They were housed under strict hygienic measures in insect-proof stables receiving balanced ration and adequate water. Also, these animals were examined and proved to be healthy and free from external and internal parasites.
Adult mice
Swiss albino weaned mice and specific pathogen-free, 21-30 days old supplied by the breeding unit, Veterinary Serum and Vaccine Research Institute, Abbasia, Cairo, Egypt were used for toxicity test of different concentrations of Montanide Gel 01 TM , titration of the virus, and evaluation of the immune response of the prepared vaccines.
2.Tissue Culture Cells
Baby Hamster Kidney cells (BHK21), were grown and maintained according to Macpherson and stocker (1962) , and were used for propagation and titration of RVF virus, vaccine production.
3.Virus
The original Rift Valley Fever (RVF) virus was isolated from a human patient in Zigzag, Sharkia Province, Egypt and supplied by NUMRU -3. It was designated as ZH501 with a titer of 10 7.5 TCID 50 / ml.
4.Samples Blood samples
Serum samples were collected from sheep before and after vaccination with the prepared vaccines. Sera were stored at -20 o C and inactivated at 56 o Cfor 30 minutes before being used in the serological studies (SNT and ELISA).
Heparinized blood samples
Jugular blood samples from vaccinated and non-vaccinated sheep were collected with anticoagulant (heparin 20-40 IU/ ml) for evaluation of cell-mediated immune response by lymphocyte blastogenesis assay, phagocytic activity test and measuring of interleukin 6 and 12.
5.Reagents, kits and media 5.1. Adjuvants:
Aluminium hydroxide gel: The gel was obtained from (Alliance Bio Company, USA), was used in a concentration of 20% for local vaccine preparation. Montanide Gel 01 TM : Montanide Gel 01 TM is based on synthetic polymer classified in the category of high molecular weight polyacrylic acid. It is a white, opaque and flowable gel. Its characteristic viscosity and its ability to work under all pH conditions make it very easy to handle. It is available in preserved or sterile autoclaved grades. It elicits humoral and cell-mediated immune response without mortality, toxicity or pyrogenic effect, simple to formulate, produced stable emulsion with stability at least 1 year at 4 o C. It was obtained from Seppic, Paris, France. 
RVF antigen
5.6.Candida albicans:
It was kindly supplied by the department of microbiology. The central lab for quality control veterinary biological products, it was used in macrophage activity test.
5.7.Fycoll-hypaque:
(Lymphocyte separation medium), used for the separation of mononuclear leukocyte cells from peripheral blood.
Roswer Park Memorial Institute (RPMI-1640)
Medium: RPMI-1640 tissue culture medium with Lglutamine, sodium bicarbonate and antibiotics, was obtained from Flow Lab, UK. Medium sterilization by filtration through a Millipore filter (0.22 μm, Sartorius, Germany) followed by storage at 4°C until used in lymphocyte blastogenesis assay and phagocytic activity test.
Methyl alcohol:
It is Methanol free from acetone (99.7%). Country of origin is Germany, from Sigma Company. It was used as 0.3 cm/well for macrophage activity test.
Giemsa stain:
It was used for phagocyte staining blood sample.
5.11.Fetal bovine serum:
supplied by GIBCO, limited, U.K. used for separation of blood lymphocytes.
5.12.Cell proliferation kit (Mdbiosciences-USA):
The kit was used in the lymphocyte blastogenesis assay Cat #: 409005.
5.13.Regents for total RNA extraction from mice lymphocytes using Trizol:
Trizol reagent (Invitrogen, Carlsbad, CA). Phenol crystals. Tris base. Distilled water. Concentrated HCL to adjust PH of Tris HCL. Chloroform. Isopropyl alcohol. 75% ethanol in RNA free water. RNA free water.
5.14.Reagents and kits for 1st strand cDNA synthesis:
Anchored oligo (dT) 18 primer. Transcriptor 1st strand cDNA synthesis kit (Roche,) using Access Quick RT-PCR (Promega, USA)Cat. No. A1702 of 100 reactions. 
Reagents and kits for
METHODS
1.Toxicity test of different concentrations of Montanide Gel 01TM Adjuvantin adult mice
Different concentrations of Montanide Gel 01 TM adjuvant in media were prepared (10%, 15%, 20 and 25%), for each concentration 10 mice were inoculated (I/P 0.2 ml/mice) and kept under daily observation for 10 days post-inoculation (OIE 2012).
2.Adsorption test
To detect the most suitable concentration of the adjuvant that can adsorb the efficient amount of antigen by adding each concentration of Montanide Gel 01 TM to known virus titre 10 7 TCID 50 / 0.1 ml and then centrifuge the mixture at 1500 rpm for 15 minutes, then titrate the virus remained in the supernatant fluid.
3.Inactivation process: using BEI according to
Blackburn and Besselaar (1991).
4.Checking the inactivation process
Samples from the inactivated virus were checked for the presence of active virus as follows: Safety in Tissue culture: according to OIE (2012). Safty in baby mice: according to El Nimr (1980) and Eman (1995).
5.Preparation of RVF vaccine batches
Preparation of 2 batches of inactivated RVF vaccine as follow:
5ˋ-ACTTTGGCTGAGGTTTGGTCTG-3ˋ
Batch 1: using Aluminium hydroxide gel 20% concentration as an adjuvant. Batch 2: using Mmontanide gel 20% concentration as an adjuvant. 6.Evaluation of the prepared vaccine batches 6.1. Sterility test: The prepared vaccines were tested for their freedom from Mycoplasma, aerobic, and anaerobic bacteria, fungi.
Potency test:
Fivefold dilutions of each vaccine were prepared in suitable media starting from 1:1 to 1:625. Five groups of adult mice. (21-28 days old) were used for each dilution and each mouse was inoculated with two doses 0.2 ml of the vaccine I/P, one week apart. Seven days after the second inoculation, all animals were challenged via I/P route with 0.1 ml of RVF virus containing10 4 MIPD 50 / ml. In addition to the other two groups of mice, one group was inoculated with challenge virus as positive control and the other group was kept as a non-vaccinated nonchallenged negative control (OIE, 2012).
All groups of mice were kept under observation for 21 days and deaths were recorded daily. The ED 50 / ml was calculated according to the method of Reed and Muench, (1938) .
Deaths occurring during the first day were considered nonspecific.
7.Sheep vaccination
Twenty five sheep of 3 -4 months old were kept in an isolated place and were divided into 5 groups (5 animals/group) as follows:-Group 1: Each animal vaccinated (S/C) with 1ml of inactivated aluminium hydroxide gel adjuvanted RVF vaccine as one dose. Group 2: Each animal vaccinated (S/C) with 1ml of inactivated aluminium hydroxide gel adjuvanted RVF vaccine in two doses Group 3: Each animal vaccinated (S/C) with 1ml of inactivated 20% Montanide Gel 01 TM adjuvanted RVF vaccine as one dose. Group 4: Each animal vaccinated (S/C) with 1ml of inactivated 20% Montanide Gel 01 TM adjuvanted RVF vaccine in two doses. Group 5: kept as non-vaccinated (control negative).
8.Collection of Samples  For evaluation of the humoral immune
response: Sera samples were collected from all sheep before and after vaccination at intervals of 7, 14, 28 days and then monthly for 12 months.
(Samples were collected in sterile dry clean screwcapped bottles, then left at room temperature for 1-2 hours or incubated for 30 minutes then placed in refrigerator overnight, then serum was removed by using sterile pasture pipette and centrifuged at 3000 rpm for 10 minutes), then kept at -20°C until used for antibody detection.
 For cell-mediated immune response: blood samples collected on heparin with intervals of 1,3,5,7,10 and 15 days post-vaccination. 
9.Evaluation of the humoral immune response
Evaluation of cell-mediated immune response 10.1. Evaluation of cell-mediated immune response by lymphocyte blastogenesis using XTT assay:
The cleavage of the tetrazolium salt (3-[4, 5dimethyl thiazole-2yl]-2,5 -diphenyl tetrazolium bromide) into a blue coloured product (formazan) by the mitochondrial enzyme succinate dehydrogenase 
Evaluation of the phagocytic activity of macrophages by using Candida Albicans: i) Separation and cultivation of mononuclear cells:
According to Aronthey and Hazen (1988). ii) Evaluation of phagocytic activity: Phagocytic %: It was performed by the method of Harmon and Glisson, (1989), which was modified by Hussein, (1989) 
11.Statistical analysis:
The obtained data were statistically analysed by (SPSS system, version 16) to estimate mean ± standard error (ST) and ANOVA for the effects of treatment and time on parameters under investigation (SPSS, 2007) .
RESULTS
1.Toxicity test for different concentrations of
Montanide Gel 01 TM Adjuvant:
All examined concentrations of Montanide Gel 01TM have no toxic effect and causing no deaths in inoculated mice as shown in table (1). 2.Adsorbtion test for selecting the suitable concentration of the adjuvant in tissue culture: Table ( 2) showed that the first concentration of Montanide Gel 01 TM that showed no cytopathic effect in tissue culture was 20% so we used this concentration in the prepared vaccine and no virus detected after titration. 
3.2.Potency test in mice:
Both Aluminium hydroxide gel and Montanide Gel 01TM inactivated RVF vaccines gave an acceptable ED 50 /ML (permissible limit 0.02/ml) as shown in table (3). It was noticed that, cell proliferation expressed by optical density was early high in Gp.3 but more strong in Gp.4 and a slight elevation in Gp.1 and 2 as shown in table (6). Values with different alphabetic within the right column showed highly significant difference at P < 0.01. Phagocytic activity was expressed by phagocytic percentage and phagocytic index in different groups as shown in table (7) and (8). It was noticed that there was early high macrophage activity in Gp.(3) but more strong in Gp.(4) and nearly slight elevation in Gp.(1) and (2). Values with different alphabetic within the right column showed highly significant difference at P < 0.01.
Phagocytic activity test:
6.3.Detection of interferon γ in the blood of mice using Syber green quantitative real-time PCR:
The real-time PCR results revealed that sheep vaccinated with Montanide Gel 01TM inactivated RVF vaccine and boostered 2 weeks apart showed high level of interleukin 6 and 12 as shown in table (9) and (10) and they gradually increased till reach high level in the 7 th -day post-vaccination, when compared with the level of interleukin 6 and 12 in groups vaccinated with one dose or two doses of Aluminium hydroxide inactivated RVF vaccine. The control results revealed no interleukin 6 and 12 gene expression Values with different alphabetic within the right column showed highly Significant difference at P < 0.01.
DISCUSSION
The progress in vaccine production is directed towards the selection of the proper adjuvant that can elaborate high and long-standing immunity. Adjuvants are considered one of the important factors in vaccine formulations as it can influence the immunity and increase the immune response referred to the vaccine. So this study was applied to evaluate the immune response and duration of immunity in sheep vaccinated with 20% Montanide Gel 01 TM inactivated RVF vaccine in comparison to aluminium hydroxide gel inactivated RVF vaccine Toxicity test of Montanide Gel 01 TM adjuvant were done by I/P inoculation of adult mice, with four concentrations of Montanide Gel 01 TM (10%, 15%, 20 and 25%) which revealed no signs of toxicity during 10 days post-inoculation as shown in table (1).
The results of adsorption test revealed that the most suitable concentration of Montanide Gel 01 TM was 20% as it was the first concentration showed no cytopathic effect of the supernatant after centrifugation when inoculated in tissue culture and no virus detected by titration as shown in table (2) . Sterility test showed that the vaccines were free from any bacterial, fungal and mycoplasma contaminations, these results agreed with OIE (2012) that revealed the vaccine batch must be free from bacteria, fungus and mycoplasma. by applying clinical examination on the vaccinated sheep, no abnormal signs were observed, no elevation of body temperature and no postvaccinal reaction at the site of injection.
Evaluating the potency of the prepared vaccines in adult mice as shown in table (3), revealed that the vaccines gave protection in mice with ED 50 /ml (0.0017 and 0.0011/ml) for the inactivated RVF vaccines with aluminium hydroxide gel, Montanide Gel 01 TM 20%) respectively. Serum neutralization test revealed that sheep vaccinated with one dose Aluminum hydroxide inactivated RVF vaccine showed that the neutralizing antibodies started to rise from the 1st-week post-vaccination (0.9 log 10 ) and reached the protective level (1.7 log 10 ) on the 2nd week postvaccination as shown in table (4), and then reached the peak (3 log 10 ) at the 2nd month post-vaccination and continue in protective level till 8th month postvaccination, these results were in agreement with those obtained by El Nimr (1980) and Eman (1995) who recorded that the protective NI level obtained by the inactivated vaccines within 2 weeks post-vaccination, the neutralizing antibody reaches the peak (2.6 logs 10 ) at the 2nd month post-vaccination and continue within the protective level till 6th month post-vaccination.
This results agreed with that obtained by Heba, (2013) who found protective antibody level of sheep vaccinated with inactivated RVF vaccine till 7 months post-vaccination while in sheep vaccinated with two doses of aluminium hydroxide gel, the NI level reached the protective level (1.7 log 10 ) at the 2 nd -week postvaccination and reached to the peak at 2 nd -month postvaccination and continue in protective level till the 10 th -month post-vaccination. In sheep vaccinated with one dose and two doses of Montanide Gel 01 TM inactivated RVF vaccines (20%), the neutralizing antibodies started to rise after vaccination to reach its protective level (2.04 log 10 and 2.07 log 10 ) respectively on the 1 st week postvaccination, and increased gradually to its peak (3.82 log 10 ) at the 3 rd month post-vaccination in sheep vaccinated with one dose and in sheep vaccinated with two doses reached the peak at 2 nd month postvaccination (3.99 log 10 ) and stay within the protective level (1.7 log 10 and 1.7 log 10 ) respectively at the (11 th month and 13 th -month post-vaccination respectively as shown in table (4).
These Moreover, confirmation of humoral immune response was assessed by ELISA as shown in table (5) as it is considered the sensitive and accurate test to evaluate the immune status of RVF in animals sera (Taha et al., 2002 and Fafetine et al., 2007) . When the ELISA test was done on the same serum samples, the results were in parallel course with that obtained by SNT. Similar findings were reported by Eman, (1995) and Mona, (2008).
Results of cell proliferation expressed by optical density were high in sheep vaccinated with one dose of Montanide Gel 01 TM inactivated RVF vaccine but more strong in sheep vaccinated with two doses of Montanide Gel 01 TM inactivated RVF vaccine as shown in table (6) . While in sheep vaccinated with one dose of AL(OH) 3 gel inactivated RVF vaccine showed slight elevation of cell proliferation and these results agreed with that obtained by Hammad (2015) who recorded slight elevation in sheep vaccinated by RVF vaccine with Aluminium hydroxide gel.
Results of phagocytic activity expressed by phagocytic percentage and phagocytic index showed early significant in sheep vaccinated with one dose of Montanide Gel 01 TM inactivated RVF vaccine as shown in table (8) and (9) but more strong in sheep vaccinated with two doses of Montanide Gel 01 TM inactivated RVF vaccine and nearly no significance in sheep vaccinated with one dose of AL (OH) 3 gel inactivated RVF vaccine which agreed with Hammad, (2015). IL 6 and IL 12 play an important role in the generation of cell-mediated immunity (Irene et al., 1999), So in this study, by using RT-PCR the level of IL6 and IL12 gene expression was detected in sheep vaccinated with different doses of Montanide Gel 01 TM inactivated RVF vaccine. The results revealed that two doses of Montanide Gel 01 TM inactivated RVF vaccine induced a higher level of IL 6 and IL12 gene expressions than Aluminium hydroxide gel inactivated RVF vaccine as shown in table (10).
CONCLUSION
From the obtained results, it can be cocluded that, Montanide Gel 01 TM was highly immunogenic when used as adjuvant in preparation of RVF vaccine inducing a higher level of antibody titre with prolonged duration of immunity, higher cell proliferation and phagocytic activity and IL6 and IL12 level so allowing a better control of the disease, so we recommend it to be used in animal vaccination to increase the level and duration of immune response.
